Overview

Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Instituto de Olhos de Goiania
Treatments:
Aflibercept
Criteria
Inclusion Criteria:

- Myopic and CNVM

Exclusion Criteria:

- Patients with poor compliance

- Patients with uncontrolled diabetes and hypertension or any other medical condition
that increase the risk of complications like recent history of Stroke or myocardial
infraction (< one year). (Physician clearance was obtained for all patients).

- Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM
following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis
which is FDA approved.

- Patients who had undergone major surgery 28 days before, were excluded from the study
and it was also suspended prior to elective surgery.

- Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant
macular oedema (CSME) etc. that affects vision and does not respond adequately to
usual treatment methods.

- Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR.

- Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM.